Pau Capetillo (@paucapetillog) posted a response video on TikTok addressing accusations about GLP-1 medications, racking up 2.2 million views. Without being able to see the specific claims made in this response video, we can't evaluate the accuracy of their statements about semaglutide, tirzepatide, or related medications.
What does this video actually claim?
The video appears to be Capetillo's response to user @Kika25, calling it their "favorite accusation." However, without access to the actual video content, we can't identify the specific claims being made about GLP-1 receptor agonists like Ozempic, Wegovy, or Mounjaro.
This is problematic because GLP-1 content on social media often contains misinformation. The STEP trials for semaglutide and SURMOUNT trials for tirzepatide provide clear data on these medications' efficacy and side effects. Any discussion of these drugs should reference actual clinical data.
Capetillo has previously posted about weight management topics, but without seeing this specific video, we can't determine whether they're making accurate statements about dosing, side effects, or expected outcomes.
What do we actually know about GLP-1 medications?
The clinical evidence for GLP-1 receptor agonists is strong and specific. Semaglutide at 2.4mg (Wegovy) produced 14.9% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). Tirzepatide at 15mg led to 20.9% weight reduction in the SURMOUNT-1 study (Jastreboff et al., NEJM, 2022).
These medications work by mimicking the GLP-1 hormone, which slows gastric emptying and reduces appetite. Common side effects include nausea, vomiting, and diarrhea, particularly during dose escalation.
Starting doses are typically 0.25mg weekly for semaglutide, increasing gradually to the maintenance dose of 2.4mg. The drugs aren't magic pills and require lifestyle changes for optimal results.
What misinformation circulates about these drugs?
TikTok is filled with problematic claims about GLP-1 medications. Common myths include the idea that you can eat whatever you want while taking them, or that weight loss is permanent without continued use.
The STEP 1 extension study showed that participants who stopped semaglutide regained about two-thirds of their lost weight within a year. This contradicts claims that these medications provide permanent weight loss.
Another frequent misconception involves "Ozempic face," a term that lacks clinical definition. While rapid weight loss can affect facial appearance, this isn't specific to GLP-1 medications. The phenomenon occurs with any significant weight reduction.
What should you know about GLP-1 social media content?
Always verify claims about these medications against published clinical trials. The FDA approval process for semaglutide and tirzepatide involved thousands of participants across multiple studies spanning several years.
Be skeptical of content creators who don't cite specific studies or provide vague claims about "amazing results." Real clinical data shows average weight loss percentages, not cherry-picked success stories.
For accurate information about GLP-1 medications, consult healthcare providers rather than social media influencers. These are prescription medications with specific indications, contraindications, and monitoring requirements that can't be adequately covered in short-form video content.